MIRAE ASSET
HEALTHCARE FUND - (MAHCF)
(Sectoral/Thematic Fund - An open ended equity scheme investing in healthcare and allied sectors)
| Type of Scheme | Sectoral/Thematic Fund - An open ended equity scheme investing in healthcare and allied sectors |
| Investment Objective | The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. The Scheme does not guarantee or assure any returns. |
Fund Manager** |
Mr. Vrijesh Kasera (since July 02, 2018) |
| Allotment Date | 02nd July, 2018 |
| Benchmark Index | S&P BSE Healthcare Index (TRI) |
| Minimum Investment Amount |
₹ 5,000/- and in multiples of ₹ 1/-thereafter. Minimum Additional Application Amount: ₹ 1,000/- per application and in multiples of ₹ 1/- thereafter. |
Systematic Investment Plan (SIP) (Any Date SIP is available from 1st July, 2019) |
Monthly and Quarterly: ₹ 1,000/- (multiples of ₹ 1/- thereafter), minimum 5 installments |
| Load Structure | Entry load: NA Exit load: I. For investors who have opted for SWP under the plan: a) 15% of the units allotted (including Switch-in/STP - in) on or before completion of 365 days from the date of allotment of units: Nil. b) Any redemption in excess of such limits in the first 365 days from the date of allotment shall be subject to the following exit load: (Redemption of units would be done on First In First Out Basis (FIFO): •If redeemed within 1 year (365 days) from the date of allotment: 1% •If redeemed after 1 year (365 days) from the date of allotment: NIL II. Other Redemptions: For Investors who have not opted for SWP under the plan (including Switch out, STP out): •If redeemed within 1 year (365 days) from the date of allotment: 1% •If redeemed after 1 year (365 days) from the date of allotment: NIL |
| Plans Available | Regular Plan and Direct Plan |
| Options Available | Growth Option and Dividend Option (Payout & Re-investment) |
| Monthly Average AUM (₹ Cr.) as on February 28, 2021 |
1,230.45 |
| Net AUM (₹ Cr.) | 1,210.99 |
| Monthly Avg. Expense Ratio (Including Statutory Levies) as on February 28, 2021 |
Regular Plan: 2.16% Direct Plan: 0.59% |
| **For experience of Fund Managers Click Here | |
| NAV: | Direct | Regular |
| Growth | ₹ 18.990 | ₹ 18.195 |
| Dividend | ₹ 18.987 | ₹ 18.190 |
| Portfolio Turnover Ratio^ | 0.37 times |
@The Volatility, Beta, R Squared, Sharpe Ratio & Information Ratio are calculated on returns from last three years Monthly data points. # Risk free rate: FBIL OVERNIGHT MIBOR as on 27th February, 2021. ^Basis last rolling 12 months. |
|
| New Position Bought |
| Chemicals |
| Deepak Nitrite Limited |
| Positions Increased |
| Chemicals |
| Chemcon Speciality Chemicals Limited |
| Rossari Biotech Limited |
| Finance |
| ICICI Lombard General Insurance Company Limited |
| Max Financial Services Limited |
| Healthcare Services |
| Apollo Hospitals Enterprise Limited |
| Pesticides |
| PI Industries Limited |
| Pharmaceuticals |
| Laurus Labs Limited |
| Sanofi India Limited |
| Positions Decreased |
| Stock |
| Chemicals |
| Vinati Organics Limited |
| Healthcare Services |
| Apollo Hospitals Enterprise Limited |
| Gland Pharma Limited |
| Pharmaceuticals |
| Ajanta Pharma Limited |
| Alkem Laboratories Limited |
| Aurobindo Pharma Limited |
| Biocon Limited |
| Cipla Limited |
| Divi's Laboratories Limited |
| Dr. Reddy's Laboratories Limited |
| IPCA Laboratories Limited |
| Lupin Limited |
| Natco Pharma Limited |
| Sun Pharmaceutical Industries Limited |
| Torrent Pharmaceuticals Limited |
| Portfolio Holdings | % Allocation | |
| Pharmaceuticals | ||
| Sun Pharmaceutical Industries Ltd | 12.04% | |
| Dr. Reddy's Laboratories Ltd | 10.10% | |
| Divi's Laboratories Ltd | 8.63% | |
| Cipla Ltd | 8.00% | |
| Torrent Pharmaceuticals Ltd | 5.59% | |
| IPCA Laboratories Ltd | 5.31% | |
| Lupin Ltd | 4.77% | |
| Aurobindo Pharma Ltd | 4.58% | |
| Natco Pharma Ltd | 3.72% | |
| Biocon Ltd | 3.34% | |
| Ajanta Pharma Ltd | 2.76% | |
| Laurus Labs Ltd | 2.36% | |
| Alkem Laboratories Ltd | 2.00% | |
| JB Chemicals & Pharmaceuticals Ltd | 1.87% | |
| Syngene International Ltd | 1.21% | |
| Abbott India Ltd | 0.48% | |
| Sanofi India Ltd | 0.06% | |
| Healthcare Services | ||
| Apollo Hospitals Enterprise Ltd | 5.57% | |
| Dr. Lal Path Labs Ltd | 2.83% | |
| Gland Pharma Ltd | 2.62% | |
| Chemicals | ||
| Vinati Organics Ltd | 2.44% | |
| Deepak Nitrite Ltd | 2.15% | |
| Chemcon Speciality Chemicals Ltd | 1.00% | |
| Rossari Biotech Ltd | 0.40% | |
| Finance | ||
| Max Financial Services Ltd | 1.52% | |
| ICICI Lombard General Insurance Company Ltd | 1.42% | |
| SBI Life Insurance Company Ltd | 1.22% | |
| Industrial Products | ||
| SRF Ltd | 1.83% | |
| Pesticides | ||
| PI Industries Ltd | 0.10% | |
| Equity Holding Total | 99.90% | |
| Cash & Other Receivables | 0.10% | |
| Total | 100.00% | |
| Returns (%) | ||||
| 1 Yr | SI | |||
| MAHCF | 59.25 |
59.29 |
||
| Scheme Benchmark* | 55.95 |
17.25 |
||
| Additional Benchmark** | 62.49 |
14.58 |
||
| NAV as on 26th Febraury, 2021 | 18,195 | |||
| Index Value (26th February, 2021) | Index Value of Scheme benchmark is 23,502.04 and S&P BSE Sensex (TRI) is 72,642.78. | |||
| Allotment Date | 02nd July, 2018 | |||
| Scheme Benchmark | *S&P BSE Healthcare Index (TRI) | |||
| Additional Benchmark | **S&P BSE Sensex (TRI) | |||
Note:1. Different Plans under the scheme has different expense structure. The reference and details provided herein are of Regular Plan - Growth Option
2. Fund manager : Mr. Vrijesh Kasera managing the scheme since July, 2018
| Period | Total Amount Invested | Mkt Value as on 26-Febraury-2021 |
SI |
310,000 |
476,869 |
1 Yr |
120,000 |
146,945 |
Returns (%) |
Period |
|
SI |
1yr |
|
Fund Return& (%) |
35.82 |
45.07 |
Benchmark Return& (%) |
28.28 |
44.96 |
Add. Benchmark Return& (%) |
22.15 |
64.29 |
& The SIP returns are calculated by XIRR approach assuming investment of ₹ 10,000/- on the 1st working day of every month.
This product is suitable for investors who are seeking*
• To generate long term capital appreciation
• Investments in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sector in India
• Degree of risk – Very High
*Investors should consult their financial advisers if they are not clear about the suitability of the product.
Past Performance may or may not be sustained in future.
Note : For computation of since inception returns (%) the allotment NAV has been taken as ₹ 10.00. The performance of other funds managed by the same fund manager is given in the respective page of the schemes 